References
- Srivastava PK. Interaction of heat shock proteins with peptides and antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002; 20: 395–425
- Parmiani G, Testori A, Maio M, Castelli C, Rivoltini L, Pilla L, Belli F, Mazzaferro V, Coppa J, Patuzzo R, Sertoli MR, Hoos A, Srivastava PK, Santinami M. Heat shock proteins and their use as anticancer vaccines. Clin Cancer Res 2004; 10: 8132–8141
- Nicchitta CN. Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity. Nature Rev Immunol 2003; 3: 427–432
- Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+cells. Nature Immunol 2005; 6: 593–599
- Rivoltini L, Castelli C, Carrabba MA, Mazzaferro V, Pilla L, Huber V, Coppa J, Gallino G, Scheibenbogen C, Squarcina P, Cova A, Camerini R, Lewis JJ, Srivastava PK, Parmiani G. Human tumor-derived heat shock proteins 96 mediates in vitro activation and in vivo expansion of melanoma and colon carcinoma-specific T cells. J Immunol 2003; 171: 3467–3474
- Noessner E, Gastpar R, Milani V, Brandl A, Hutzler PJS, Kuppner MC, Roos M, Kremmer E, Asea A, Calderwood SK, Issels RD. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002; 169: 5424–5432
- Staib F, Distler M, Bethke K, Schmitt U, Galle PR, Heike M. Cross-presentation of human melanoma peptide antigen MART-1 to CTLs from in vitro reconstituted gp96/MART-1 complexes. Cancer Immun 2004; 4: 3
- Belli F, Testori A, Rivoltini L, Maio M, Andreola S, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchiano A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G. Vaccination of metastatic patients with autologous tumor-derived heat shock proteins gp96. J Clin Oncol 2002; 20: 4169–4180
- Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor imunity. Proc Nat Acad Sci USA 1993; 90: 3539–3543
- Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, Maurichi A, Massarut S, Marchiano A, Santatonio C, Tosi D, Arienti F, Cova A, Sovena G, Pins A, Nonaka D, Bersani I, Florio AD, Luigi M, Srivastava PK, Hoos A, Santanami M, Parmiani G. A phase II trial of vaccination with autologous, tumor-derived heat shock protein peptide complex Gp96, in combination with GM-CSF and interferon α in metastatic melanoma patients. Cancer Immunol Immunother. published online. 2005
- Mazzaferro V, Coppa J, Carrabba MA, Rivoltini L, Schiavo M, Regalia F, Mariani L, Camarini T, Marchianò A, Andreola S, Camerini R, Corsi M, Lewis JJ, Srivastava PK, Parmiani G. Vaccination with autologous tumor-derived heat shock proteins gp96 after liver resection for metastatic colon cancer. Clin Cancer Res 2003; 9: 3235–3245